This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 Jun;10(6):312-3.

doi: 10.1038/nrclinonc.2013.72. Epub 2013 Apr 30.

Targeted therapies: HER2-positive breast cancer-sifting through many good options

Ian E Krop¹

Affiliations

PMID: 23629473
DOI: 10.1038/nrclinonc.2013.72

Comment

Targeted therapies: HER2-positive breast cancer-sifting through many good options

Ian E Krop. Nat Rev Clin Oncol. 2013 Jun.

. 2013 Jun;10(6):312-3.

doi: 10.1038/nrclinonc.2013.72. Epub 2013 Apr 30.

Author

Ian E Krop¹

Affiliation

¹ Dana-Farber Cancer Institute, Harvard University School of Medicine, Breast Oncology Center, 450 Brookline Avenue, Boston, MA 02215, USA. ikrop@partners.org

PMID: 23629473
DOI: 10.1038/nrclinonc.2013.72

No abstract available

PubMed Disclaimer

Comment on

Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
Guan Z, Xu B, DeSilvio ML, Shen Z, Arpornwirat W, Tong Z, Lorvidhaya V, Jiang Z, Yang J, Makhson A, Leung WL, Russo MW, Newstat B, Wang L, Chen G, Oliva C, Gomez H. Guan Z, et al. J Clin Oncol. 2013 Jun 1;31(16):1947-53. doi: 10.1200/JCO.2011.40.5241. Epub 2013 Mar 18. J Clin Oncol. 2013. PMID: 23509322 Clinical Trial.

Similar articles

Reply to F. Ades.
Guan Z. Guan Z. J Clin Oncol. 2013 Nov 20;31(33):4272. doi: 10.1200/JCO.2013.52.4520. Epub 2013 Oct 14. J Clin Oncol. 2013. PMID: 24127453 No abstract available.
Lapatinib versus placebo added to paclitaxel in first-line human epidermal growth factor receptor 2-positive metastatic breast cancer: ethical lessons not learned from Africa.
Ades F. Ades F. J Clin Oncol. 2013 Nov 20;31(33):4271. doi: 10.1200/JCO.2013.51.0289. Epub 2013 Oct 14. J Clin Oncol. 2013. PMID: 24127451 No abstract available.
Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
Guan Z, Xu B, DeSilvio ML, Shen Z, Arpornwirat W, Tong Z, Lorvidhaya V, Jiang Z, Yang J, Makhson A, Leung WL, Russo MW, Newstat B, Wang L, Chen G, Oliva C, Gomez H. Guan Z, et al. J Clin Oncol. 2013 Jun 1;31(16):1947-53. doi: 10.1200/JCO.2011.40.5241. Epub 2013 Mar 18. J Clin Oncol. 2013. PMID: 23509322 Clinical Trial.
[Novel target therapies used in breast cancer management].
Semiglazova TIu, Semiglazov VV, Filatova LV, Gershanovich ML, Chudenko VA, Latipova DKh, Luk'ianchikova VS, Dashian GA, Paltuev RM. Semiglazova TIu, et al. Vopr Onkol. 2011;57(5):592-600. Vopr Onkol. 2011. PMID: 22238928 Review. Russian. No abstract available.
Lapatinib in breast cancer: clinical experiences and future perspectives.
Giampaglia M, Chiuri VE, Tinelli A, De Laurentiis M, Silvestris N, Lorusso V. Giampaglia M, et al. Cancer Treat Rev. 2010 Nov;36 Suppl 3:S72-9. doi: 10.1016/S0305-7372(10)70024-4. Cancer Treat Rev. 2010. PMID: 21129615 Review.

See all similar articles

References

1. J Clin Oncol. 2013 Jun 1;31(16):1947-53 - PubMed
1. Lancet Oncol. 2012 Feb;13(2):135-44 - PubMed
1. J Clin Oncol. 2009 Apr 20;27(12):1999-2006 - PubMed
1. J Clin Oncol. 2013 Mar 20;31(9):1157-63 - PubMed
1. Clin Cancer Res. 2009 Feb 15;15(4):1452-9 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal